Text Size

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of California, Los Angeles.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00346372
First received: June 27, 2006
Last updated: June 17, 2010
Last verified: February 2009
History of Changes
  Purpose

During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular tumors may lead to improved diagnosis and monitoring of tumors within the eye.


Condition
Ocular Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Estimated Enrollment: 800
Study Start Date: March 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who meet the following Eligibility Criteria

Criteria

Inclusion Criteria:

  • Adults (18 years or older) with:

    • choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:
    • choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)

Exclusion Criteria:

  • Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346372

Contacts
Contact: Tara A McCannel, MD, PhD (310) 206-7484 tmccannel@jsei.ucla.edu
Contact: Sandy Yin, M.S. 310 206 7484 yin@jsei.ucla.edu

Locations
United States, California
Jules Stein Eye Institute Recruiting
Los Angeles, California, United States, 90095
Contact: sandy yin     310-206-7484     yin@jsei.ucla.edu    
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Bradley R Straatsma, MD, JD Jules Stein Eye Institute, UCLA
  More Information

No publications provided

Responsible Party: Tara McCannel, M.D., Ph.D., University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00346372     History of Changes
Other Study ID Numbers: UCLA IRB#03-11-052
Study First Received: June 27, 2006
Last Updated: June 17, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
Ocular Melanoma
Optical Coherence Tomography
Eye Tumor
Choroidal Melanoma
Uveal Melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on May 23, 2013